Neoprobe completes financing

By staff writers

December 8, 2008 -- Gamma camera probe developer Neoprobe has wrapped up a $3 million investment in convertible preferred stock and warrants by Platinum-Montaur Life Sciences (Montaur).

Montaur has now invested $13 million in the Dublin, OH-based firm.

In other Neoprobe news, the company said that a phase III trial of its Lymphoseek radiopharmaceutical found a concordance rate of 96% with Lymphoseek and patient blue dyes. The trial studied the use of Lymphoseek in breast cancer and melanoma patients.

Neoprobe gets OK for Lymphoseek study, April 16, 2008

Neoprobe announces phase II Lymphoseek results, March 13, 2008

Neoprobe nets financing, December 27, 2007

Neoprobe extends agreement with Ethicon, December 20, 2007

Neoprobe, Cardinal Health ink distribution deal, November 28, 2007

Copyright © 2008


To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking